Close Menu

NEW YORK (GenomeWeb) – Epigenomics today reported a 55 percent drop in its 2017 revenues, a decline the company attributed in part to fewer orders for its Epi proColon colorectal cancer test.

For the year ended Dec. 31, Epigenomics posted revenues of €1.9 million ($2.3 million) from €4.2 million the year before. Revenues of about 1.3 million were generated through licensing income, while product sales for the year were approximately 500,000, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.